Night shift work, chronotype and prostate cancer risk in the MCC-Spain case-control study.


Por: Papantoniou K, Castaño-Vinyals G, Espinosa A, Aragonés N, Pérez-Gómez B, Burgos J, Gómez-Acebo I, Llorca J, Peiró R, Jimenez-Moleón JJ, Arredondo F, Tardón A, Pollan M and Kogevinas M

Fecha de Publicación: 01/09/2015
Resumen:
Night shift work has been classified as a probable human carcinogen based on experimental studies and limited human evidence on breast cancer. Evidence on other common cancers, such as prostate cancer, is scarce. Chronotype is an individual characteristic that may relate to night work adaptation. We evaluated night shift work with relation to prostate cancer, taking into account chronotype and disease severity in a population based case-control study in Spain. We included 1,095 prostate cancer cases and 1,388 randomly selected population controls. We collected detailed information on shift schedules (permanent vs. rotating, time schedules, duration, frequency), using lifetime occupational history. Sociodemographic and lifestyle factors were assessed by face-to-face interviews and chronotype through a validated questionnaire. We used unconditional logistic regression analysis adjusting for potential confounders. Subjects who had worked at least for one year in night shift work had a slightly higher prostate cancer risk [Odds Ratio (OR) 1.14; 95%CI 0.94, 1.37] compared with never night workers; this risk increased with longer duration of exposure (= 28 years: OR 1.37; 95%CI 1.05, 1.81; p-trend = 0.047). Risks were more pronounced for high risk tumors [D'Amico classification, Relative Risk Ratio (RRR) 1.40; 95%CI 1.05, 1.86], particularly among subjects with longer duration of exposure (=28 years: RRR 1.63; 95%CI 1.08, 2.45; p-trend = 0.027). Overall risk was higher among subjects with an evening chronotype, but also increased in morning chronotypes after long-term night work. In this large population based study, we found an association between night shift work and prostate cancer particularly for tumors with worse prognosis.

Direcciones
Papantoniou K: Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Bioanalysis Research Group, IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
Castaño-Vinyals G: Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Bioanalysis Research Group, IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
Espinosa A: Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Bioanalysis Research Group, IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain
Aragonés N: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Carlos III Health Institute, Madrid, Spain; Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta De Hierro, Madrid, Spain
Pérez-Gómez B: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Carlos III Health Institute, Madrid, Spain; Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta De Hierro, Madrid, Spain
Burgos J: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; Servicio De Urología, Hospital Ramón Y Cajal, Madrid, Spain; Instituto Ramón Y Cajal De Investigación Sanitaria (IRYCIS), Madrid, Spain; Universidad De Alcalá De Henares, Madrid, Spain
Gómez-Acebo I: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; University of Cantabria, Santander, Spain; IDIVAL, Santander, Spain
Llorca J: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; University of Cantabria, Santander, Spain; IDIVAL, Santander, Spain
Peiró R: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; FISABIO SALUD PÚBLICA - GENÓMICA Y SALUD, Valencia, Spain
Jimenez-Moleón JJ: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; Department of Preventive Medicine and Public Health, Instituto De Investigación Biosanitaria Ibs.GRANADA, Hospitales Universitarios De Granada/Universidad De Granada, Granada, Spain
Arredondo F: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; Hospital Infanta Elena, Huelva, Spain; Centro De Investigación En Salud Y Medio Ambiente (CYSMA), Universidad De Huelva, Spain
Tardón A: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; IUOPA, Universidad De Oviedo, Asturias, Spain
Pollan M: CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Carlos III Health Institute, Madrid, Spain; Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta De Hierro, Madrid, Spain
Kogevinas M: Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain; Bioanalysis Research Group, IMIM (Hospital Del Mar Medical Research Institute), Barcelona, Spain; Universitat Pompeu Fabra (UPF), Barcelona, Spain; CIBER Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain; National School of Public Health, Athens, Greece
ISSN: 00207136





INTERNATIONAL JOURNAL OF CANCER
Editorial
WILEY-BLACKWELL, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 137 Número: 5
Páginas: 1147-1157s
WOS: 000356429000015
ID de PubMed: 25530021

MÉTRICAS